AOA 2023: Diving into new data on MiSight contact lenses for myopia management

Video

At AOA Optometry's Meeting 2023, in Washington, DC, Justin Kwan, OD, FAAO, provides updates on the latest at CooperVision, including new data on MiSight myopia management contact lenses and information on their ortho-K software, Visavy.

Justin Kwan, OD, FAAO, caught us up with the latest at CooperVision as he outlined key findings from 20 scientific abstracts that they presented at the 2023 British Contact Lens Association (BCLA) Meeting.

Video transcript

Editor's note: this transcript has been lightly edited for clarity.

Justin Kwan, OD, FAAO:
So, CooperVision, we just came off with the BCLA meeting in the UK, Manchester specifically, and CooperVision is so proud to have presented 20 scientific abstracts presentations. It is one of the core values to be so evidence based in all that we do, learning so much from, not only our 7 year MiSight study, but beyond, and these kids that started at age eight to 12, that are now young adults.

So, I wanted to highlight a couple of those findings. First, is the quality of vision. I think there's this misperception that adults that were myopia control devices and optics, they don't see very clear. But, from a quality of vision standpoint, these young adults actually did very well and did not give up on their myopia control device, simply because the optics are what they are. So, they function very well.

We also found that in year 7 of the study, we intentionally took the subjects out of MiSight, the treatment was removed. Some of them actually got a little bit worse, but the vast majority did not have a rebound effect. So to treat them at the start of year 8, they were already right back into a reduced myopia progression rate, which is so great to see [at] all these ages. they're still getting the benefit that we desire, so that this disease doesn't keep getting worse.

Lastly, we have our ortho-K software based design called Visavy. [It's] so exciting that even with 20 plus years of CRT in the US marketplace, we continue to learn, improve and innovate. This typography-guided design can not only make you a beautiful lens, but the success rate is what doctors rely on and desire. We found [a] 97% success rate, and only two eyes that required another order to fine tune that fit. That really benefits patients, doctors, and staff alike, [and] makes for very happy patients. Those are some of the quick 3 hitting things from BCLA.

Recent Videos
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.